Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03271021 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
A Phase 3 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,488
- Enrollment target
NCT03271021 is a Phase 3 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 1,488 participants.
The verdict
NCT03271021, a Phase 3 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,488 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
Interventions
- DRUG Vehicle Foam
- DRUG FMX101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,488 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03271021
The ClinicalTrials.gov registry entry for NCT03271021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT03271021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03271021 about?
NCT03271021 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris". A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
What is the current status of trial NCT03271021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,488 participants. The study started on 2017-07-17. Estimated completion is 2018-09-04.
What interventions are being tested in trial NCT03271021?
The interventions under investigation include: Vehicle Foam (DRUG), FMX101 (DRUG).
Who is sponsoring clinical trial NCT03271021?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.